The main objective of this observational study is to characterize new users of quetiapine XR as well as new users of other study drugs (i.e. the comparison group) and to quantify the risk of developing newly diagnosed outcomes of interest in new users of quetiapine XR as well as in other study drugs.
Epidemiology study to assess the safety of a new slow-release form of Seroquel (quetiapine) in the post-marketing phase in the UK.
Study Type
OBSERVATIONAL
Enrollment
37,372
University Hospital Basel
Basel, Switzerland
The outcome of interest will be evaluated by means of relative risk based on incidence rates estimates in users of quetiapine XR vs corresponding incidence rates in users of comparison drugs
Time frame: During follow-up of a treatment episode estimated to be on average of 1.5 years
Duration of treatment
Time frame: During follow-up estimated to be on average of 1.5 years.
Duration of treatment episode
Episode, defined as the treatment time from first to last prescription of quetiapine XR or other study drugs.
Time frame: During follow-up estimated to be on average of 1.5 years
Comorbidities defined by clinical diagnosis or prescription
Time frame: Baseline and during follow up of treatment estimated to be on average 1.5 years
Age
Time frame: Baseline
Gender
Time frame: Baseline
Dose
Time frame: During follow-up of treatment estimated to be on average 1.5 years
Adherence
Time frame: During follow-up of treatment estimated to be on average 1.5 years
The number of subjects to whom the drug was prescribed by the general practitioners.
The number of patients, whom the drug was prescribed by the specified type of prescriber (specialist, general practitioner or another type of physician).
Time frame: During follow-up of treatment estimated to be on average 1.5 years
Indication for treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: During follow-up of treatment estimated to be on averaged 1.5 years